Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1215Neoplasms 1024Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 687Colorectal Neoplasms 590Lung Neoplasms 572Pancreatic Neoplasms 394Leukemia, Myeloid, Acute 394Neoplasm Metastasis 387Ovarian Neoplasms 370Multiple Myeloma 369Stomach Neoplasms 316Carcinoma, Hepatocellular 301Melanoma 281Brain Neoplasms 277Recurrence 273Squamous Cell Carcinoma of Head and Neck 267Head and Neck Neoplasms 237Endometrial Neoplasms 234Glioblastoma 233Triple Negative Breast Neoplasms 228Uterine Cervical Neoplasms 221Precursor Cell Lymphoblastic Leukemia-Lymphoma 221Lymphoma 221Sarcoma 201Hematologic Neoplasms 199Urinary Bladder Neoplasms 196Esophageal Neoplasms 190Carcinoma, Renal Cell 187Lymphoma, Non-Hodgkin 175

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Inoperable Locally Advanced HER2-Negative Breast Cancer × 1 year × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡